

RESEARCH ARTICLE

# Racial and ethnic disparities in medication adherence among privately insured patients in the United States

Zhiwen Xie<sup>1</sup>, Patricia St. Clair<sup>2</sup>, Dana P. Goldman<sup>3\*</sup>, Geoffrey Joyce<sup>4</sup>

**1** Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, California, United States of America, **2** Data Core, Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, California, United States of America, **3** Schools of Public Policy, Pharmacy, and Economics, University of Southern California, Los Angeles, California, United States of America, **4** Department of Pharmaceutical & Health Economics, USC School of Pharmacy, Los Angeles, California, United States of America

\* [dana.goldman@usc.edu](mailto:dana.goldman@usc.edu)



**OPEN ACCESS**

**Citation:** Xie Z, St. Clair P, Goldman DP, Joyce G (2019) Racial and ethnic disparities in medication adherence among privately insured patients in the United States. PLoS ONE 14(2): e0212117. <https://doi.org/10.1371/journal.pone.0212117>

**Editor:** John M. Ruiz, University of Arizona, UNITED STATES

**Received:** August 8, 2018

**Accepted:** January 28, 2019

**Published:** February 14, 2019

**Copyright:** © 2019 Xie et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** This study used a 25% sample of De-identified Clinformatics Data Mart (OptumInsight, Eden Prairie, MN), a large-scale claims dataset of privately insured patients with both medical and pharmacy coverage from a large commercial insurer in the United States from 2011 to 2013. The authors used a portion of the patient populations in this sample who satisfied their patient selection criteria, detailed in the text. Authors in this study have the right to use this dataset, but not the right to share and distribute. Interested parties can contact OPTUM at 1-866-386-3404.

## Abstract

### Objective

To examine the association between socioeconomic status (SES) and racial and ethnic disparities in medication adherence for three widely prescribed therapeutic classes

### Methods

We linked longitudinal claims data from a large US-based insurance provider (2011–2013) to detailed SES information to identify patients treated with oral antidiabetic (N = 56,720), antihypertensive (N = 156,468) or antihyperlipidemic (N = 144,673) medications. We measured adherence and discontinuation by therapeutic class, and conducted regression analysis to quantify the contributions of different factors in the association between race/ethnicity and medication adherence.

### Results

During an average follow-up period of 2.5 years, average adherence rates of Blacks and Hispanics were at least 7.5 percentage points lower than those of Whites. Controlling for demographics, health status, out-of-pocket costs, convenience of refilling prescriptions and SES attenuated the association by 30 to 50 percent, nonetheless substantial racial disparities persisted (4.1–5.8 percentage points), particularly for asymptomatic conditions. Separating adherence among existing users from those that discontinued therapies indicates that racial/ethnic disparities in adherence reflect inconsistent pill-taking rather than differential rates of discontinuation.

### Conclusions

Racial/ethnic disparities in adherence are mitigated, but persist after controlling for detailed socioeconomic measures. Interventions should focus more on improving medication adherence of existing users, particularly in treating asymptomatic conditions.

**Funding:** This research was supported by the National Institute on Aging under award number P30AG024968, which supports the Roybal Center for Health Policy Simulation, and award number P01AG033559 at the University of Southern California. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This study used a 25% sample of De-identified Clinformatics® Data Mart (OptumInsight, Eden Prairie, MN), a large-scale claims dataset of privately insured patients with both medical and pharmacy coverage from a large commercial insurer in the United States from 2011 to 2013.

**Competing interests:** Dr. Goldman serves as a consultant to Precision Health Economics and holds equity in its parent company. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The remaining authors have nothing to disclose.

**Abbreviations:** SES, Socioeconomic Status; PDC, Proportion of Days Covered; MPR, Medication Possession Ratio; T2DM, Type 2 Diabetes Mellitus; OOP, Out-of-Pocket.

## Introduction

Chronic medications must be taken as prescribed to be effective, yet poor adherence is endemic [1–10]. Nearly half of all patients that were prescribed pharmaceutical therapies do not take sufficient doses to experience therapeutic benefits [11]. Suboptimal medication-taking behavior, consisting of poor adherence among existing users and discontinuation of therapy, is particularly acute in racial/ethnic minority populations. Minorities typically have higher prevalence of chronic disease, worse access to medical care, and greater financial constraints [12–15]. Past studies suggest that Blacks and Hispanics are at least 50 percent more likely to have suboptimal adherence rates than Whites, and that differences in socioeconomic status (SES) may play a significant role in explaining these deficits [5,16].

A large number of U.S. studies have documented suboptimal medication adherence and discontinuation across a wide range of patient populations and disease conditions, but few have examined the association after controlling for detailed measures of socioeconomic status such as income and education [9,10,13,16]. Studies that rely on pharmacy claims usually lack information on a patient's race/ethnicity and socioeconomic well-being, at best inferring differences in SES from averages of large geographic units such as zip codes or census tracts [6,7,16]. By contrast, studies that rely on survey data include more accurate and detailed socio-demographic information, but rely on self-reported adherence measures, which are shown to overestimate actual adherence [12,17–19].

In this paper, we linked longitudinal pharmacy and medical claims to detailed demographic and socioeconomic data on privately insured patients to compare race-specific rates of medication adherence and discontinuation to commonly prescribed medications used to treat hypertension, hyperlipidemia, and Type 2 diabetes mellitus (T2DM). We also seek to identify the impacts of adjusting for socioeconomic status (SES) on the association between race/ethnicity and medication adherence, which can inform appropriate interventions to help reduce disparities in adherence and health outcomes.

## Methods

### Data & sample selection

This study used a 25% sample of De-identified Clinformatics Data Mart (OptumInsight, Eden Prairie, MN), a large-scale claims dataset of privately insured patients with both medical and pharmacy coverage from a large commercial insurer in the United States from 2011 to 2013.

We linked enrollment data to medical and pharmacy claims over time for commercially insured members and their dependents. The enrollment data included information on patients' plan type, coverage period, gender, and year of birth. The prescription claims included information on the date of each prescription, type of drug, brand and generic name, active ingredient, and days of supply, as well as financial information such as the copayment and deductible associated with each claim. The medical claims captured standard information, including date of service, diagnosis codes, and duration of hospital stays.

Our study focused on chronic medications treating T2DM, hypertension, and hyperlipidemia, three of the most prevalent and costly chronic conditions in the United States [20]. We identified patients taking medications for these conditions by examining their prescription drug claims and enrollment files. We selected individuals age 18 to 64, not enrolled in a Medicare Advantage plan. To ensure at least a year of follow-up, we included individuals who filled two or more prescriptions in the therapeutic class in 2011 or 2012 and were continuously enrolled in the same benefit plans through December 31<sup>st</sup>, 2013. Based on these inclusion criteria, our study sample consisted of 56,720 (3.9 percent) beneficiaries taking oral antidiabetics,

156,468 (10.9 percent) beneficiaries taking antihypertensive medications, and 144,673 (10.1 percent) beneficiaries taking antihyperlipidemic medications (See Table A1 in [S1 File](#) for details of sample selection). The average follow-up period was 2.4, 2.5, and 2.5 years for patients on oral antidiabetic, antihypertensive, and antihyperlipidemic medications, respectively.

### **Socioeconomic variables & race/ethnicity**

In addition to the standard demographic information, the claims data were linked to a detailed set of SES measures for each beneficiary, including race/ethnicity, education level, and household income. Race was either self-reported or derived from a combination of public records, purchase transactions, and consumer surveys [21]. Education at the census block group level was derived from U.S. Census data. (Census block group is the smallest unit on which the Census bureau publishes sample data. It has a population of 600 to 3,000 people. It is smaller than a Census Tract, and larger than a Census Block.) OPTUMInsight has ensured that the dataset is statistically de-identified and consistent with all HIPAA requirements.

### **Adherence measures—proportion of days covered (PDC) and discontinuation**

Poor adherence can be a product of three different behavioral pathways: reduced initiation of treatment, worse adherence among existing users, and/or discontinuation of therapy. Since we could not infer primary nonadherence (patients who were prescribed a medication but never initiated therapy), we focused on secondary adherence of patients after they initiated a therapy [22–24]. We used proportion of days covered (PDC) to measure adherence behavior of current users. PDC is a well-established method for measuring adherence using claims data [22,23,25,26] and offers a more conservative estimate compared to the medication possession ratio (MPR) [22,27]. We measured adherence at the effective ingredient level. In cases where a patient was on multiple medications within the same therapeutic class, the patient was considered adherent for a particular day if he or she was covered by at least one of the medications within the therapeutic class. We defined the observation period from the date of first fill within the therapeutic class to the last day of 2013, excluding days when the patient was hospitalized.

To more accurately reflect adherence among active users, we identified patients who discontinued therapy altogether. Patients were considered to have discontinued a therapy if they were not in possession of any drug in the class for at least 180 days. By this definition, 24 to 26 percent of patients discontinued treatment in the approximately 30-month follow-up period ([S1 Table](#)). For patients that discontinued a therapy, we measured their adherence only for the period when they were taking the medication, defined as the period from the date of the first observed fill to the last day of possession in the follow-up period.

### **Statistical analysis—multivariate regressions**

We first examined differences in adherence by race/ethnicity in each therapeutic class. To understand the contribution of different observable factors in racial/ethnic disparities in adherence rates [28], we performed stepwise linear regressions. We started with a baseline specification with patient-level PDC as the dependent variable and binary indicators for each race/ethnicity. In turn, we added: patient demographics (age in log form, gender and geographic area of residence defined by census division), comorbid conditions (Charlson comorbidity index, and other chronic drugs taken within the observation period (on an active ingredient level)), out-of-pocket (OOP) costs (calculated as the average copay and deductible per day of supply of medication), percentage of medication obtained through mail order

pharmacy, average days of supply per prescription, education (categorical variable), and household income (categorical variable). Education and income were entered last, as one of our primary objectives was to examine how SES variables moderated the association between race/ethnicity and medication adherence after controlling for patient demographics and insurance status. Throughout this process, we observed how racial/ethnic differences in adherence rates changed with additional controls and whether these changes varied across the three therapeutic classes. We hypothesized that controlling for a richer set of socioeconomic variables would further weaken the racial and ethnic disparities in medication adherence. While this exercise cannot establish a causal relationship, it provides an estimate of the relative effects of SES compared to standard demographic controls, comorbidities and plan characteristics, including patient cost-sharing and convenience of refilling medications.

As a second step, we performed two sets of logistic regression models, by therapeutic class, to quantify and compare the relative risk of suboptimal adherence (PDC < 0.8) and the likelihood of discontinuing therapy altogether. These models adjusted for all the covariates included in the previous analysis. The regression coefficients were then used to predict odds ratios by race/ethnicity of suboptimal adherence and discontinuation.

All statistical analyses were conducted using Stata version 14.1.

## Results

[S1 Table](#) shows the characteristics of the study sample, by therapeutic class. Overall, 56 percent of patients in the sample were male, with an average age of 52.6 years. While the majority were white, Blacks and Hispanics made up a disproportionate share of those taking oral antidiabetic medications. Users of oral antidiabetic medications had lower levels of educational attainment and household income, and more comorbidities than those taking antihypertensive or cholesterol-lowering medications. Nearly three-fourths of the study sample were enrolled in a point of service plan.

[S2 Table](#) shows average (unadjusted) adherence rates by race, education and income in each therapeutic class. Average adherence was highest among patients taking antihypertensives (78.4 percent, oral antidiabetic 74.7 percent, antihypertensive 75.3 percent), and among those taking medications in 2 or 3 of the classes analyzed (35.7%). Further, there were significant differences by race/ethnicity, education and income. Non-White, low educational attainment, and low household income were associated with lower adherence rates in all three classes. For example, the average adherence rate among whites taking an oral antidiabetic was 8.4 percentage points higher than Hispanics, which is equivalent to one less month (31 days) of medication use per year. The mean PDC of patients in the lowest income bracket (<\$40K) was 9.4 percentage points lower than those in the highest income bracket (>\$100K), equivalent to 34 less days covered by medication in a year.

[S3 Table](#) shows how racial/ethnic gradients in adherence changed as we added additional sets of covariates. The baseline model reports unadjusted differences for each racial/ethnic group relative to whites, similar to [S2 Table](#). For example, the average PDC of Hispanics is 7.9 to 9.2 percentage points lower than whites. Similarly, the average PDC of blacks is 7.5 to 8.7 percentage points lower than whites without adjustment. Controlling for the full set of covariates reduces these differences by 30% to 50% across the three drug classes. For example, the average PDC of Hispanics is 4.1 to 5.8 percentage points lower than whites after adjustment, while the black-white differential is reduced to 4.3 to 5.2 percentage points. Average adherence rates of Asians are only modestly lower than whites before adjustment, and remain similar in absolute terms in the full model. The average PDC of Asians is 1.1 to 3.3 percentage points lower than whites after adjustment.

[S4 Table](#) compares the adjusted odds of discontinuing therapy and having suboptimal adherence (PDC <0.8) for each race/ethnicity relative to whites, by therapeutic class. Blacks and Hispanics are more likely to discontinue an antihyperlipidemic (odds ratio of 1.15, 1.30 respectively), but not antihypertensive or antidiabetic medications after adjustment. On the other hand, blacks and Hispanics actively using these chronic medications are 36 to 59 percent more likely to have poor adherence than Whites, defined as a PDC < .80.

## Discussion

We found that controlling for socioeconomic characteristics reduced, but did not eliminate the association between race/ethnicity and medication adherence. Average adherence rates of blacks and Hispanics were 4.8 to 6.5 percentage points lower than whites across three widely used drug classes, which translates to about 20–25 fewer days of medication use per year. We found smaller racial/ethnic differences in adherence to medications for more symptomatic conditions such as antidiabetics, wherein the consequences of poor adherence are more evident to the patient. While blacks and Hispanics take these medications less consistently than whites, they were not at higher risk for discontinuing a medication, although the results varied by therapeutic class. This suggests that reducing disparities in adherence should focus on improving daily adherence rather than cessation of therapy.

Prior work has shown that higher adherence is associated with better management of chronic conditions (A1C, LDL, and blood pressure), lower hospitalizations, and reduced mortality risk [29–33]. For example, Ho et al found that nonadherence to antihypertensive and antihyperlipidemic medications was associated with a 10 to 40 percent relative increase in risk of cardiovascular hospitalizations and a 50 to 80 percent higher risk of mortality [33]. Thus, even modest improvements in the medication adherence of minorities has potential to narrow observed differences in health across race/ethnicity.

Our findings are generally consistent with the previous literature, but smaller in magnitude [5,6,16]. This is likely due to better controls for socioeconomic status, which has been shown to be strongly correlated with better health and health behaviors [34,35]. We also hypothesized that racial/ethnic differences in adherences may be driven by differential rates of discontinuation. Patients commonly discontinue therapy, either at the direction of their provider, or more commonly, on their own due to side-effects, perceived ineffectiveness, distrust of physician's recommendations, or cost [9,36–38]. Prior work typically measures adherence over a pre-determined period of time, such as a calendar year or twelve months after an initial fill date, underestimating overall adherence rates and often categorizing those who have stopped taking a medication as poor adherers. While this is an important methodological distinction, it did not explain differences in average adherence by race/ethnicity. Previous studies have also shown that the convenience and duration of getting prescription refills was associated with improved adherence [16,36,39]. In our study, we also found that black and Hispanic patients had fewer 90-day fills and less frequent use of mail-order pharmacies than whites and Asians (Tables A6 and A7 in [S1 File](#)). Controlling for average days of supply per fill and the use of mail-order pharmacy further attenuated racial/ethnicity disparities, but significant differences persisted.

Our study has several limitations. First, while pharmacy claims have been widely used to estimate adherence, they do not measure actual pill-taking behavior. Second, our study sample consists of younger, privately insured patients of above-average SES. Thus, our results may not generalize to lower SES groups such as a Medicaid population. Third, we measure adherence among those actively using a medication, excluding periods when patients have discontinued therapy for at least 6 months. We conservatively used 180 days, but there is no standard

definition of discontinuation or persistence to a chronic medication. Using this definition, we found that about 1 in 5 patients discontinued their chronic medication over an average follow-up of 2.5 years. Defining discontinuation based on a gap of 90 days or more reduced the number of patients stopping therapy and lowered average adherence rates, but did not substantively change adherence rates differentially across race/ethnicity. Lastly, our regression results do not yield a causal explanation for non-adherence, rather they provide estimates of the effects of education, income and race separately on adherence, which can guide potential interventions for moderating these differences.

## Public health implications

Our findings indicate that non-white patients were no more likely to discontinue a medication than whites; rather, they took their chronic medications less consistently. While changing patient behavior is difficult, prescription drug claims and electronic medical records allow for real-time interventions via text message or low-cost reminder devices that could prove impactful for non-White patients who have gaps in coverage. Alternatively, such data could be monitored to identify patients who did not refill a medication in a timely fashion, eliciting a call from a pharmacist, nurse or health care provider to understand the reason for nonadherence and intervene if appropriate. The combination of real-time pharmacy claims and the near universal adoption of electronic devices could potentially prove more cost-effective than previous approaches to improving adherence, although there is no conclusive evidence on the long-term effectiveness of patient reminders [40,41].

## Supporting information

**S1 Table. Characteristics of patients by therapeutic class.**

(DOCX)

**S2 Table. Average adherence rates (PDC) by race, education and household income.**

(DOCX)

**S3 Table. Contribution of factors towards explaining the racial gradient in medication adherence.**

(DOCX)

**S4 Table. Adjusted odds ratio of discontinuation and nonadherence (PDC<0.8) by race/ethnicity.**

(DOCX)

**S1 File. Supplemental tables.**

(XLSX)

## Author Contributions

**Conceptualization:** Zhiwen Xie, Dana P. Goldman, Geoffrey Joyce.

**Data curation:** Patricia St. Clair.

**Formal analysis:** Zhiwen Xie.

**Supervision:** Patricia St. Clair, Dana P. Goldman, Geoffrey Joyce.

**Writing – original draft:** Zhiwen Xie.

**Writing – review & editing:** Patricia St. Clair, Dana P. Goldman, Geoffrey Joyce.

## References

1. Holmes HM, Luo R, Hanlon JT, Elting LS, Suarez-Almazor M, Goodwin JS. Ethnic disparities in adherence to antihypertensive medications of medicare part D beneficiaries. *J Am Geriatr Soc.* 2012; 60(7):1298–303. Epub 2012/06/19. <https://doi.org/10.1111/j.1532-5415.2012.04037.x> PMID: 22702464; PubMed Central PMCID: PMC3396714.
2. Lauffenburger JC, Robinson JG, Oramasionwu C, Fang G. Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction. *Circulation.* 2014; 129(7):754–63. Epub 2013/12/12. <https://doi.org/10.1161/CIRCULATIONAHA.113.002658> PMID: 24326988; PubMed Central PMCID: PMC351731.
3. Zhang Y, Baik SH. Race/Ethnicity, disability, and medication adherence among medicare beneficiaries with heart failure. *J Gen Intern Med.* 2014; 29(4):602–7. Epub 2013/12/25. <https://doi.org/10.1007/s11606-013-2692-x> PMID: 24366395; PubMed Central PMCID: PMC3965752.
4. Hussein M, Waters TM, Chang CF, Bailey JE, Brown LM, Solomon DK. Impact of Medicare Part D on racial disparities in adherence to cardiovascular medications among the elderly. *Med Care Res Rev.* 2016; 73(4):410–36. Epub 2015/11/19. <https://doi.org/10.1177/1077558715615297> PMID: 26577228.
5. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. *JAMA.* 2002; 288(4):455–61. PMID: 12132975.
6. Trinacty CM, Adams AS, Soumerai SB, Zhang F, Meigs JB, Piette JD, et al. Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study. *BMC Health Serv Res.* 2009; 9:24. Epub 2009/02/10. <https://doi.org/10.1186/1472-6963-9-24> PMID: 19200387; PubMed Central PMCID: PMC2645384.
7. Lewey J, Shrank WH, Avorn J, Liu J, Choudhry NK. Medication adherence and healthcare disparities: impact of statin co-payment reduction. *Am J Manag Care.* 2015; 21(10):696–704. Epub 2015/12/04. PMID: 26633094.
8. Choudhry NK, Bykov K, Shrank WH, Toscano M, Rawlins WS, Reisman L, et al. Eliminating medication copayments reduces disparities in cardiovascular care. *Health Affairs.* 2014; 33(5):863–70. Epub 2014/05/07. <https://doi.org/10.1377/hlthaff.2013.0654> PMID: 24799585.
9. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. *JAMA.* 2007; 298(1):61–9. <https://doi.org/10.1001/jama.298.1.61> WOS:000247721100022. PMID: 17609491
10. Alsabbagh MHDW, Lemstra M, Eurich D, Lix LM, Wilson TW, Watson E, et al. Socioeconomic status and nonadherence to antihypertensive drugs: A systematic review and meta-analysis. *Value in Health.* 2014; 17(2):288–96. <https://doi.org/10.1016/j.jval.2013.11.011> PMID: 24636389
11. Haynes RB, McKibbin KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. *Lancet.* 1996; 348(9024):383–6. PMID: 8709739.
12. Heisler M, Faul JD, Hayward RA, Langa KM, Blaum C, Weir D. Mechanisms for racial and ethnic disparities in glycemic control in middle-aged and older Americans in the health and retirement study. *Arch Intern Med.* 2007; 167(17):1853–60. Epub 2007/09/26. <https://doi.org/10.1001/archinte.167.17.1853> PMID: 17893306.
13. Adams AS, Trinacty CM, Zhang F, Kleinman K, Grant RW, Meigs JB, et al. Medication adherence and racial differences in A1C control. *Diabetes Care.* 2008; 31(5):916–21. Epub 2008/02/01. <https://doi.org/10.2337/dc07-1924> PMID: 18235050; PubMed Central PMCID: PMC2563955.
14. Lewey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. *Am Heart J.* 2013; 165(5):665–78, 78 e1. <https://doi.org/10.1016/j.ahj.2013.02.011> PMID: 23622903.
15. Saha S, Freeman M, Toure J, Tippens KM, Weeks C, Ibrahim S. Racial and ethnic disparities in the VA health care system: a systematic review. *J Gen Intern Med.* 2008; 23(5):654–71. Epub 2008/02/28. <https://doi.org/10.1007/s11606-008-0521-4> PMID: 18301951; PubMed Central PMCID: PMC324157.
16. Adams AS, Uratsu C, Dyer W, Magid D, O'Connor P, Beck A, et al. Health system factors and antihypertensive adherence in a racially and ethnically diverse cohort of new users. *JAMA Intern Med.* 2013; 173(1):54–61. Epub 2012/12/12. <https://doi.org/10.1001/2013.jamainternmed.955> PMID: 23229831; PubMed Central PMCID: PMC35105889.
17. Gerber BS, Cho YI, Arozullah AM, Lee SY. Racial differences in medication adherence: A cross-sectional study of Medicare enrollees. *Am J Geriatr Pharmacother.* 2010; 8(2):136–45. Epub 2010/05/05. <https://doi.org/10.1016/j.amjopharm.2010.03.002> PMID: 20439063; PubMed Central PMCID: PMC3740123.

18. Adams AS, Soumerai SB, Lomas J, Ross-Degnan D. Evidence of self-report bias in assessing adherence to guidelines. *Int J Qual Health Care*. 1999; 11(3):187–92. Epub 1999/08/06. PMID: [10435838](#).
19. Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. *Translational behavioral medicine*. 2015; 5(4):470–82. Epub 2015/12/02. <https://doi.org/10.1007/s13142-015-0315-2> PMID: [26622919](#); PubMed Central PMCID: [PMCPMC4656225](#).
20. Chronic Disease Prevention and Health Promotion. In: H. Barrett D, W. Ortmann L, Dawson A, Saenz C, Reis A, Bolan G, editors. *Public Health Ethics: Cases Spanning the Globe*. Cham: Springer International Publishing; 2016.
21. Wells TS, Ozminkowski RJ, Hawkins K, Bhattarai GR, Armstrong DG. Leveraging big data in population health management. 2016; 1(1):1. <https://doi.org/10.1186/s41044-016-0001-5>
22. Sattler EL, Lee JS, Perri M. Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. *Drugs & Aging*. 2013; 30(6):383–99. Epub 2013/04/05. <https://doi.org/10.1007/s40266-013-0074-z> PMID: [23553512](#).
23. Capoccia K, Odegard PS, Letassy N. Medication adherence with diabetes medication: A systematic review of the literature. *Diabetes Educ*. 2016; 42(1):34–71. Epub 2015/12/08. <https://doi.org/10.1177/0145721715619038> PMID: [26637240](#).
24. Raebel MA, Schmittiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. *Medical care*. 2013; 51(8 Suppl 3):S11–21. Epub 2013/06/19. <https://doi.org/10.1097/MLR.0b013e31829b1d2a> PMID: [23774515](#); PubMed Central PMCID: [PMCPMC3727405](#).
25. Gu Q, Zeng F, Patel BV, Tripoli LC. Part D coverage gap and adherence to diabetes medications. *Am J Manag Care*. 2010; 16(12):911–8. Epub 2011/02/26. PMID: [21348561](#).
26. Peacock E, Krousel-Wood M. Adherence to Antihypertensive Therapy. *The Medical clinics of North America*. 2017; 101(1):229–45. Epub 2016/11/26. <https://doi.org/10.1016/j.mcna.2016.08.005> PMID: [27884232](#); PubMed Central PMCID: [PMCPMC5156530](#).
27. Nau D. Proportion of days covered (PDC) as a preferred method of measuring medication adherence 2011. Available from: <http://www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdf>.
28. Smith JP. Nature and causes of trends in male diabetes prevalence, undiagnosed diabetes, and the socioeconomic status health gradient. *Proc Natl Acad Sci U S A*. 2007; 104(33):13225–31. Epub 2007/08/19. <https://doi.org/10.1073/pnas.0611234104> PMID: [17698965](#); PubMed Central PMCID: [PMCPMC1948924](#).
29. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. *J Manag Care Pharm*. 2006; 12(3):239–45. Epub 2006/04/21. <https://doi.org/10.18553/jmcp.2006.12.3.239> PMID: [16623608](#).
30. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. *Arch Intern Med*. 2006; 166(17):1836–41. Epub 2006/09/27. <https://doi.org/10.1001/archinte.166.17.1836> PMID: [17000939](#).
31. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. *JAMA*. 2007; 297(2):177–86. Epub 2007/01/11. <https://doi.org/10.1001/jama.297.2.177> PMID: [17213401](#).
32. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. *Circulation*. 2006; 113(24):2803–9. Epub 2006/06/14. <https://doi.org/10.1161/CIRCULATIONAHA.106.618066> PMID: [16769908](#).
33. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. *Am Heart J*. 2008; 155(4):772–9. Epub 2008/03/29. <https://doi.org/10.1016/j.ahj.2007.12.011> PMID: [18371492](#).
34. Pampel FC, Krueger PM, Denney JT. Socioeconomic Disparities in Health Behaviors. *Annual Review of Sociology*. 2010; 36:349–70. Epub 2011/09/13. <https://doi.org/10.1146/annurev.soc.012809.102529> PMID: [21909182](#); PubMed Central PMCID: [PMCPMC3169799](#).
35. Braveman PA, Cubbin C, Egerter S, Williams DR, Pamuk E. Socioeconomic disparities in health in the United States: what the patterns tell us. *Am J Public Health*. 2010; 100 Suppl 1:S186–96. Epub 2010/02/12. <https://doi.org/10.2105/ajph.2009.166082> PMID: [20147693](#); PubMed Central PMCID: [PMCPMC2837459](#).



36. Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc.* 2011; 86(4):304–14. Epub 2011/03/11. <https://doi.org/10.4065/mcp.2010.0575> PMID: 21389250; PubMed Central PMCID: PMC3068890.
37. Egan M, Philipson T. Health Care Adherence and Personalized Medicine. NBER Working Paper Series. 2014:20330. <https://doi.org/10.3386/w20330>
38. Alsan M, Wanamaker M. Tuskegee and the Health of Black Men. *The Quarterly Journal of Economics.* 2017; 133(1):407–55. <https://doi.org/10.1093/qje/qjx029> PMID: 30505005
39. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. *Circulation.* 2009; 119(23):3028–35. Epub 2009/06/17. <https://doi.org/10.1161/CIRCULATIONAHA.108.768986> PMID: 19528344.
40. Choudhry NK, Krumme AA, Ercole PM, Girdish C, Tong AY, Khan NF, et al. Effect of reminder devices on medication adherence: The REMIND Randomized Clinical Trial. *JAMA Intern Med.* 2017; 177(5):624–31. <https://doi.org/10.1001/jamainternmed.2016.9627> PMID: 28241271.
41. Thakkar J, Kurup R, Laba TL, Santo K, Thiagalingam A, Rodgers A, et al. Mobile telephone text messaging for medication adherence in chronic disease: A meta-analysis. *JAMA Intern Med.* 2016; 176(3):340–9. Epub 2016/02/03. <https://doi.org/10.1001/jamainternmed.2015.7667> PMID: 26831740.